CA
LLY icon

Capital Advantage’s Eli Lilly LLY Stock Holding History

Capital Advantage’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$668K Buy
557
+24
+5% +$24.5K 0.08% 86
2026
Q1 		$490K Buy
533
+27
+5% +$27.4K 0.06% 98
2025
Q4 		$544K Sell
506
-94
-16% -$89.9K 0.07% 93
2025
Q3 		$458K Hold
600
– – 0.07% 100
2025
Q2 		$468K Buy
600
+29
+5% +$22.5K 0.07% 100
2025
Q1 		$441K Hold
571
– – 0.08% 92
2024
Q4 		$441K Buy
+571
New +$473K 0.08% 92

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Advantage's LLY Position: Q2 2026 in Review

Capital Advantage increased its Eli Lilly (LLY) stake by 4.5% in Q2 2026, buying an estimated $24.5K and bringing the position to 557 shares worth $668K. The position accounts for 0.08% of the portfolio, ranked #86.

Capital Advantage first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 4,626 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Capital Advantage held 557 shares of Eli Lilly worth $668K as of Q2 2026.
  • Capital Advantage bought 24 Eli Lilly shares in Q2 2026, an estimated $24.5K.
  • Eli Lilly made up 0.08% of Capital Advantage's portfolio in Q2 2026, its #86 holding.
  • Capital Advantage first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 4,626 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Capital Advantage's 13F filing for Q2 2026, filed 13 Jul 2026.